

Curriculum Vitae

Personal Data

Title	Prof. Dr. Dr.
First name	Robert
Name	Bals
Current position	Director, Department of Internal Medicine V
Current institution(s)/site(s)	Department of Internal Medicine V Saarland University, Homburg, German
Identifiers/ORCID	ORCID-ID: 0000-0002-1472-9535 https://scholar.google.com/citations?user=2c-tEc0AAAAJ&hl=de

Qualifications and Career

Stages	Periods and Details
Degree programme	Study of Medicine, Ludwig-Maximilians-Universität München, Germany, 1987-1994 Study of Biology, Ludwig-Maximilians-Universität München, Germany, 1991-1995
Doctorate	1994 Doctoral Thesis Medicine, Anatomy, LMU Munich, Germany 1999 Doctoral Thesis Biology, Zoology, LMU Munich, Germany
Stages of academic/professional career	<ul style="list-style-type: none"> • since 2010 Full Professor (W3) for Internal Medicine and Pulmonology, Saarland University • 2001-2010 Resident and Apl. Professor, Department for Internal Medicine, Division of Pulmonology, Philipps-Universität Marburg, Marburg • 1999-2001 Resident, Medizinische Klinik und Poliklinik I, Klinikum Großhadern, LMU Munich • 1996-1999 Postdoctoral researcher, University of Pennsylvania, Institute for Human Gene Therapy, Philadelphia, USA • 1994-1996 Resident, Institute for Anatomy and Medizinische Klinik, Klinikum Innenstadt, LMU Munich • 1994-1996 Resident, Ludwig-Maximilians-Universität, Zoologisches Institut München

Supplementary Career Information N/A

Engagement in the Research System

- Editor in Chief, Respiratory Research, 2019-
- Associate Editor, European Respiratory Journal, 2016-2018
- Chief Editor, Respiratory Monograph, ERS, 2014-1016
- Member of the Senate of the Saarland University, 2018-
- Member of the Sachverständigenkommission für die anwendungsorientierten und mündlich-praktischen Prüfungen Medizin beim IMPP (2022-2023)
- Member of the Fachkollegiums Pneumologie der DFG (2019-2023)
- Research Director of the European Respiratory Society (2010-2013)
- Vertrauensdozent der Studienstiftung des Deutschen Volkes (2021-)

Supervision of Researchers in Early Career Phases N/A

Scientific Results

Category A

1. Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S, Klug M, Schunk SJ, Schmit D, Kramann R, Korbel C, Ampofo E, Laschke MW, Selejan SR, Paschen A, Herter T, Schuster S, Silbernagel G, Sester M, Sester U, Assmann G, **Bals R**, Kostner G, Jahnen-Dechent W, Menger MD, Rohrer L, Marz W, Bohm M, Jankowski J, Kopf M, Latz E, Niemeyer BA, Fliser D, Laufs U, Speer T. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. *Nat Immunol.*;21(1):30-41 (2020)
2. Trudzinski FC, Jorres RA, Alter P, Kahnert K, Waschki B, Herr C, Kellerer C, Omlor A, Vogelmeier CF, Fahndrich S, Watz H, Welte T, Jany B, Sohler S, Biertz F, Herth F, Kauczor HU, **Bals R**, consortium C. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. *Sci Rep.*;10(1):10544 (2020).
3. Herr C, Tsitouras K, Niederstrasser J, Backes C, Beisswenger C, Dong L, Guillot L, Keller A, **Bals R**. Cigarette smoke and electronic cigarettes differentially activate bronchial epithelial cells. *Respir Res.*;21(1):67, (2020)
4. Ritzmann F, Jungnickel C, Vella G, Kamyschnikow A, Herr C, Li D, Menger MM, Angenendt A, Hoth M, Lis A, **Bals R**, Beisswenger C. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer. *Sci Rep.*;9(1):10353 (2019).
5. Becker A, Vella G, Galata V, Rentz K, Beisswenger C, Herr C, Walter J, Tierling S, Slevogt H, Keller A, **Bals R**. The composition of the pulmonary microbiota in sarcoidosis - an observational, study. *Respir Res.*;20(1):46 (2019).
6. Polke M, Seiler F, Lepper PM, Kamyschnikow A, Langer F, Monz D, Herr C, **Bals R**, Beisswenger C. Hypoxia and the hypoxia-regulated transcription factor HIF-1alpha suppress the host defence of airway epithelial cells. *Innate immunity.*;23(4):373-80 (2017).
7. Jungnickel C, Schmidt LH, Bittigkoffer L, Wolf L, Wolf A, Ritzmann F, Kamyschnikow A, Herr C, Menger MD, Spieker T, Wiewrodt R, **Bals R**, Beisswenger C. IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth. *Oncogene.*;36(29):4182-90, (2017).
8. Fahndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jorres RA, Greulich T, Vogelmeier CF, **Bals R** Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. *Respir Res.*;18(1):171 (2017).

9. Wonnenberg B, Jungnickel C, Honecker A, Wolf L, Voss M, Bischoff M, Tschernig T, Herr C, **Bals R**, Beisswenger C. IL-17A attracts inflammatory cells in murine lung infection with *P. aeruginosa*. *Innate immunity*.;22(8):620-5 (2016).
10. Li D, Sun J, Liu W, Wang X, **Bals R**, Wu J, Quan W, Yao Y, Zhang Y, Zhou H, Wu K. Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-kappaB. *Oncotarget*.;5(40):66032-50 (2016).

Category B

N/A

Academic Distinctions

1999	Adolf-Windorfer-Preis Mukoviszidose e.V.
2000	Paul-Martini-Preis
2004	Alpha1-Antitrypsin Laurell's Award (ALTA)
1996-1998	Forschungstipendium of the Deutsche Forschungsgemeinschaft

Other Information

N/A

Data protection and consent to the processing of optional data

If you provide voluntary information (marked as optional) in this CV, your consent is required. Please confirm your consent by checking the box below.

I expressly consent to the processing of the voluntary (optional) information, including “special categories of personal data”¹ in connection with the DFG’s review and decision-making process regarding my proposal. This also includes forwarding my data to the external reviewers, committee members and, where applicable, foreign partner organisations who are involved in the decision-making process. To the extent that these recipients are located in a third country (outside the European Economic Area), I additionally consent to them being granted access to my data for the above-mentioned purposes, even though a level of data protection comparable to EU law may not be guaranteed. For this reason, compliance with the data protection principles of EU law is not guaranteed in such cases. In this respect, there may be a violation of my fundamental rights and freedoms and resulting damages. This may make it more difficult for me to assert my rights under the General Data Protection Regulation (e.g. information, rectification, erasure, compensation) and, if necessary, to enforce these rights with the help of authorities or in court.

I may **revoke** my consent in whole or in part at any time – with effect for the future, freely and without giving reasons – vis-à-vis the DFG (postmaster@dfg.de). The lawfulness of the processing carried out up to that point remains unaffected. Insofar as I transmit “special categories of personal data” relating to third parties, I confirm that the necessary legitimation under data protection law exists (e.g. based on consent).

¹ Special categories of personal data are those “revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and (...) genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation” (Article 9(1) GDPR).

I have taken note of the DFG's Data Protection Notice relating to research funding, which I can access at www.dfg.de/privacy_policy and I will forward it to such persons whose data the DFG processes as a result of being mentioned in this CV.